CAMP4 Therapeutics Corp (CAMP)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.74-2.35%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CAMP
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Document CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002…
Stated in 2 of 2 supplied quarters. Management reported: “Document CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP-1 related disorder; trial initiation anticipated in the fourth quarter of this year.” “Clinical trial launch is expected in Q4 2026.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Document CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights Secured regulatory clearance in two jurisdictions to initiate first-in-human Phase 1/2 clinical trial of CMP-002…”
“CAMP4 expects to advance CMP-002 into a Phase 1/2 clinical trial in individuals with SYNGAP1-related disorder in the second half of 2026.”
The Company believes that its current cash and cash equivalents will be sufficient to fund its planned activities through the end of 2028.
Stated in 1 of 2 supplied quarters. Management reported: “Second Quarter 2026 Financial Results Cash and cash equivalents as of June 30, 2026, were $86.4 million, compared to $109.5 million as of December 31, 2025.” “The Company believes that its current cash and cash equivalents will be sufficient to fund its planned activities through the end of 2028.”
“The Company believes that its current cash and cash equivalents will be sufficient to fund its planned activities through the end of 2028.”
The new data demonstrate that CMP-002 administration produced a statistically significant improvement in both seizure threshold and severity of chemically-induced tonic-clonic seizures in mice haploi…
Stated in 1 of 2 supplied quarters. Management reported: “The new data demonstrate that CMP-002 administration produced a statistically significant improvement in both seizure threshold and severity of chemically-induced tonic-clonic seizures in mice haploinsufficient for SYNGAP1.” “Together, these data suggest that restoring SYNGAP1 protein toward healthy levels with CMP-002 may improve both the neurodevelopmental and seizure phenotypes that define SRD, supporting the potential of CMP-002 to provide broad disease-modifying benefit.”
“The new data demonstrate that CMP-002 administration produced a statistically significant improvement in both seizure threshold and severity of chemically-induced tonic-clonic seizures in mice haploi…”
Over the trailing year it converted 0.89x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, long-term interest rates, the US dollar, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-04.